Luulyo 31, AstraZeneca iyo Merck & Co. waxay si wadajir ah ugu dhawaaqeen in daawada joojisa PARP ee Lynparza, oo ay weheliso Abiraterone iyo prednisolone, loo ansixiyay Shiinaha si loogu daaweeyo bukaanada qaangaarka ah ee qaba kansarka qanjirka 'prostate' ee u adkaysta castration-ka (mCRPC) kuwaas oo wata isbeddellada jeermiska ama somatic BRCA (gBRCAm ama sBRCAm).
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Iimayl:myimmnet@163.com
Lynparza (olaparib) waa daawo ka hortagta PARP ee heerka koowaad waana daaweyntii ugu horreysay ee la beegsado si loo joojiyo jawaab celinta dhaawaca DNA (DDR) ee unugyada/burooyinka oo leh yaraanta HRR, sida isbeddellada BRCA1 iyo/ama BRCA2. Joojinta PARP ee Lynparza waxay horseeddaa dabin PARP ah oo ku xiran jabka hal-xadhig ee DNA, joojinta fargeetooyinka taranka, burburkooda iyo soo saarista jabka laba-xadhig ee DNA iyo dhimashada unugyada kansarka.
Ansixintan waxaa ugu horreyn lagu saleeyay natiijooyinka falanqaynta koox-hoosaadka ee ka soo baxay kooxaha caalamiga ah iyo kuwa Shiinaha ee tijaabada PROpel Wajiga III. PROpel waa tijaabo caafimaad oo aan kala sooc lahayn, laba-indhoole ah, oo xarun badan leh oo qiimeynaysa waxtarka, badbaadada, iyo dulqaadka Lynparza iyadoo lala kaashanayo Abiraterone iyo prednisolone marka la barbar dhigo placebo iyo Abiraterone iyo prednisolone ee bukaanada labka ah ee qaba mCRPC kuwaas oo aan hore u helin kiimoterabiga ama daaweynta hoormoonka cusub (NHA) marxaladda mCRPC.
Xogta laga helay kooxda caalamiga ah ee bukaanada qaba isbeddellada BRCA waxay muujisay in Lynparza oo ay weheliso Abiraterone ay muujisay horumar muhiim ah oo caafimaad ahaan ku yimid badbaadada aan lahayn horumarka shucaaca (rPFS) marka la barbar dhigo daaweynta Abiraterone monotherapy. Falanqaynta koox-hoosaadka ee bukaanada qaba isbeddellada BRCA ee kooxda caalamiga ah ayaa muujisay in Lynparza oo lagu daray Abiraterone ay yareysay khatarta cudurka ama dhimashada 76% iyo khatarta dhimashada 70%. rPFS dhexdhexaadka ah iyo badbaadada guud ee dhexdhexaadka ah (OS) ee kooxda Lynparza iyo Abiraterone weli lama gaarin, halka rPFS dhexdhexaadka ah iyo OS dhexdhexaadka ah ee kooxda daaweynta ee Abiraterone ay ahaayeen 8 bilood iyo 23 bilood, siday u kala horreeyaan.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
Waqtiga boostada: Agoosto-07-2025